VBS Pharma

Vascular BioSciences was founded to develop products that enhance and prolong human life. At VBS, we develop disease solutions as if we were developing them for our own family
Date:Nov 24, 2013

Our lead therapeutic candidate, CARSKNKDC (CAR) peptide, represents a new paradigm in targeted therapy. CAR preferentially homes to, and penetrates, diseased tissue while selectively augmenting the efficacy of therapies and accelerating wound healing. CAR can selectively enhance gene therapy, boost drug effectiveness, and reduce systemic side effects by enhancing the targeted uptake of co-administered therapeutics.